Tags: Cancer | xgeva | bone | tumor | gctb

New Medication Fights Bone Tumors

Friday, 14 Jun 2013 03:23 PM

 

Xgeva (denosumab) has been approved by the U.S. Food and Drug Administration to treat giant cell tumor of the bone (GCTB), a rare tumor that's most often non-cancerous.

The tumor usually affects adults between ages 20 and 40, although it may also develop in adolescents, the FDA said. It typically doesn't spread, although in rare cases it can become cancerous and travel to the lungs.
 
As a non-cancerous tumor, GCTB destroys bone as it becomes larger, causing pain, fractures, and loss of mobility. Xgeva has been approved in cases where the tumor can't be surgically removed, or might lead to a severe outcome such as loss of a limb, the agency said.
 
Xgeva, approved under the FDA's expedited review program, was evaluated for this use in two clinical trials involving a total of 305 adults and adolescents. Common side effects included joint pain, headache, nausea, fatigue, back pain, and extremity pain.
 
Women of childbearing potential should use "highly effective" contraception while taking Xgeva, since the drug can harm a fetus, the FDA warned.
 
The drug was first approved in 2010 to prevent fractures when cancer has spread to the bone. It's marketed by Amgen, based in Thousand Oaks, Calif.

© HealthDay

Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

New Psoriasis Drug

Wednesday, 21 Jan 2015 16:08 PM

A new drug to treat adults with moderate-to-severe plaque psoriasis was approved Wednesday by the U.S.Food and Drug Admi . . .

Device Fights Obesity

Wednesday, 14 Jan 2015 12:47 PM

The U.S. Food and Drug Administration said on Wednesday it has approved a new device to treat obesity, the first since 2 . . .

Long-Lasting Parkinson's Drug

Monday, 12 Jan 2015 13:11 PM

The U.S. Food and Drug Administration approved AbbVie Inc's treatment for Parkinson's disease. The treatment, Duopa - a. . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved